A randomised controlled phase II trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer

Cancer Biology and Medicine

Volumn 9, Issue 2, 2012, Pages 111-114

  Lv, Jing ^a   Liu, Ning ^a   Liu, Ke Wei ^a   Ding, Ai Ping ^a   Wang, Hao ^a   Qiu, Wen Sheng ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Capecitabine; Colorectal neoplasm; Oxaliplatin; Thalidomide

Indexed keywords

AIHENG; CAPECITABINE; OXALIPLATIN; THALIDOMIDE; UNCLASSIFIED DRUG;

ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DISEASE CONTROL; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84876335010     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.02.005     Document Type: Article

References (15)

1. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
2. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
3. Noman AS, Koide N, Hassan F, et al. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun 2009; 15: 33-41.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425.
5. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-2091.
6. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
7. Conroy T, Hebbar M, Bennouna J, et al. Quality-of-life findings from a randomised phaseIII study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. Br J Cancer 2010; 102: 59-67.
8. Shiroiwa T, Fukuda T, Tsutani K. Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 2009; 101: 12-18.
9. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
10. Liu WM, Henry JY, Meyer B, et al. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009; 101: 803-812.
11. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
12. She MJ, Ma SZ, Li GZ, et al. Clinical Randomised Control Trial on Treatment of Advanced Esophageal Carcinoma by Concurrent Chemoradiotherapy Combining Thalidomide. Chin J Clin Oncol 2010; 37: 882-885 (in Chinese).
13. Govindarajan R. Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park) 2002; 16 (4 Suppl 3): 23-26.
14. McCollum AD, Wu B, Clark JW, et al. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol 2006; 29: 40-44.
15. Zhang HG, Li J, Qin SK, et al. A randomized trial of irinoteean plus fuorouraeil and leucovorin with thalidomide versus without thalidomideinthetreatmentfor advanced colorectal. Chin J Oncol 2007; 29: 228-231 (in Chinese).